With 0.59 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.5 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $87.88 whereas the lowest price it dropped to was $85.26. The 52-week range on AXSM shows that it touched its highest point at $105.00 and its lowest point at $64.11 during that stretch. It currently has a 1-year price target of $130.82. Beta for the stock currently stands at 1.02.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AXSM was down-trending over the past week, with a drop of -3.39%, but this was down by -10.65% over a month. Three-month performance dropped to -3.28% while six-month performance rose 7.70%. The stock gained 3.70% in the past year, while it has gained 8.93% so far this year. A look at the trailing 12-month EPS for AXSM yields -6.54 with Next year EPS estimates of -1.51. For the next quarter, that number is -0.96. This implies an EPS growth rate of -3.05% for this year and 72.13% for next year.
Float and Shares Shorts:
At present, 48.44 million AXSM shares are outstanding with a float of 39.61 million shares on hand for trading. On 2024-12-13, short shares totaled 6.52 million, which was 1345.0 higher than short shares on 1731628800. In addition to Dr. Herriot Tabuteau M.D. as the firm’s Founder, Chairman, CEO & President, Mr. Nick Pizzie CPA, M.B.A. serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.81071 of AXSM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AXSM reported revenue of $104762000.0 and operating income of -$46233000.0. The EBITDA in the recently reported quarter was -$44172000.0 and diluted EPS was -$1.34.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AXSM since 15 analysts follow the stock currently. There are 13 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AXSM analysts setting a high price target of 180.0 and a low target of 105.0, the average target price over the next 12 months is 130.4706. Based on these targets, AXSM could surge 107.61% to reach the target high and rise by 21.11% to reach the target low. Reaching the average price target will result in a growth of 50.49% from current levels.
Analysts have provided yearly estimates in a range of -$3.80029 being high and -$6.33382 being low. For AXSM, this leads to a yearly average estimate of -$5.43047. Based on analyst estimates, the high estimate for the next quarter is -$0.48 and the low estimate is -$1.29. The average estimate for the next quarter is thus -$0.87.
